Ado-trastuzumab emtansine biosimilar (Formosa/Eirgenix)

恩美曲妥珠单抗生物类似药 (台新药/台康生技)

Report date: 2025/07/21 16:22:51

Base Information

Drug NameAdo-trastuzumab emtansine biosimilar (Formosa/Eirgenix)
Drug Alias NameTSY-0110EG-12043TSY-110
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > MCC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM1 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) +[4] 
Mechanisms of ActionTubulin inhibitorsAnti-HER2
TargetsReceptor protein-tyrosine kinase erbB-2Tubulin
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFormosa Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesFormosa Pharmaceuticals IncEirgenix Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A